Centre Tightens Retail Norms for Cough Syrup Sale, Mandates Prescription

IMT News Desk
IMT News Desk
· 2 min read
Centre mandates prescription for cough syrup sale, removing syrups from Schedule K exemption to prevent misuse and ensure patient safety across India.

Amid growing safety concerns over the unchecked use of syrup-based medicines, the Union Health Ministry has restricted their sale to valid prescriptions only, mandating that cough syrups and other medicinal syrups will be dispensed only through duly licensed pharmacies.

Issuing a gazette notification, the ministry communicated the omission of “Syrup” from the “Class of Drugs” listed under Schedule K of the Drugs Rules, 1945, through the Drugs (Fifth Amendment) Rules, 2026, notified in the Official Gazette on June 9.

With this omission, the sale of syrup-based medicines, including cough syrups, will require a valid prescription from a registered medical practitioner and “will be dispensed only through duly licensed pharmacies, in accordance with the provisions of the Drugs and Cosmetics Act, 1940,” the ministry said in a statement.

The move effectively ends the over-the-counter (OTC) sale of these syrups across India, as under the amendment, the word “Syrups” has been removed from item number (7) under serial number 13 of Schedule K of the Drugs Rules, 1945.

Under the new directive, chemists and pharmacies can sell syrup-based medicines only after seeing a valid prescription from a registered medical practitioner, which applies not only to cough syrups but to all medicinal syrups that were previously available without prescription requirements.

According to the health ministry, “the move is expected to promote responsible distribution and sale of cough syrups while ensuring greater compliance with regulatory standards across the country,” official sources said.

By making prescriptions mandatory for syrup medicines, the government aims to reduce misuse, improve patient safety, and encourage people to seek professional medical advice before taking medication.

The change follows concerns over the safety and quality of certain India-made cough syrups that were linked to deaths and health complications in some overseas markets, authorities say.

However, officials have clarified that this is not a blanket ban on all cough syrups, with the requirement for a prescription depending on the composition and regulatory classification of each formulation.

The Union Health and Family Welfare Ministry notified the amendment to bring syrup-based formulations, including cough syrups, under stricter regulatory oversight, with the sale and dispensing of cough syrups in smaller villages now required to take place only through duly licensed pharmacies in accordance with the Drugs and Cosmetics Act, 1940 and the Rules framed under it.

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk